Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform you that following the receipt of approval from the United States Food and Drug Administration (USFDA) ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts more than Nifty Microcap 250 and 2.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Veerhealth Care received USFDA approval on 16th May 2025 for its oral care products registered under the Drug (OTC) category, and has begun supplying these products to a US customer. The company has already dispatched 3 full container load (FCL) shipments and now targets 4 to 5 shipments per month going forward. The current order is valued at Rs. 0.74 crores, to be executed within 30 days, with the customer name kept confidential under a non-disclosure agreement. The customer is an international entity, and the order is not related to the promoter or group companies. Management expects this development to positively contribute to revenues and strengthen the company's presence in regulated markets.
Positive for shareholders — USFDA approval unlocks access to the large US OTC oral care market, and a steady monthly shipment cadence could translate into recurring export revenue and improved growth visibility.